Quarterly report pursuant to Section 13 or 15(d)

Revenue - Collaboration Agreement - The GSK Termination and Transfer Agreement (Details)

v3.24.1.1.u2
Revenue - Collaboration Agreement - The GSK Termination and Transfer Agreement (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2023
GBP (£)
Jun. 30, 2023
GBP (£)
Mar. 31, 2024
USD ($)
Mar. 31, 2024
GBP (£)
Dec. 31, 2023
GBP (£)
Apr. 06, 2023
USD ($)
Apr. 06, 2023
GBP (£)
Revenue              
Revenue recognized in the period     $ 5,678,000        
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements     305,509,000        
GSK Termination and Transfer Agreement              
Revenue              
Upfront payment received | £   £ 7,500,000          
Milestone payment | £ £ 3,000,000       £ 12,000,000    
Potential milestone payments to be received | £       £ 7,500,000      
Milestone met and accrued | £       £ 6,000,000      
Amount of transaction price of the agreement at inception           $ 37,335,000  
Upfront and milestone payment receivable | £             £ 30,000,000
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements     34,495,000        
IGNYTE              
Revenue              
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements     18,325,000        
LTFU              
Revenue              
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements     $ 16,170,000